Deep PSA response and extended time-to-nadir as robust predictors of survival in Asian patients with de novo metastatic hormone-sensitive prostate cancer receiving upfront intensified treatment.
Chris H-M WongIvan C-H KoDavid K-W LeungBrian SiuCheuk-K K ChengYung-Y J LimHiu T MokChun-F B KwokCheuk Y TangSteven Chi Ho LeungPeter K-F ChiuJeremy Y-C TeohChi F NgPublished in: The Prostate (2024)
Our analysis demonstrates that alternative PSA targets can predict treatment response and survival outcomes in de novo mHSPC patients in a real-world setting, providing valuable information for patient counselling and potentially guiding future trial design.
Keyphrases
- prostate cancer
- radical prostatectomy
- end stage renal disease
- ejection fraction
- newly diagnosed
- small cell lung cancer
- chronic kidney disease
- peritoneal dialysis
- clinical trial
- case report
- prognostic factors
- study protocol
- current status
- patient reported outcomes
- phase iii
- human immunodeficiency virus
- free survival
- hiv testing
- replacement therapy
- hiv infected
- antiretroviral therapy
- double blind